XML 412 R61.htm IDEA: XBRL DOCUMENT v3.25.0.1
FAIR VALUE MEASUREMENTS (Narrative) (Details)
12 Months Ended
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Jun. 20, 2023
USD ($)
Jul. 01, 2015
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Fair value of debt $ 6,100,000,000 $ 4,600,000,000      
Invigorate Program          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Total restructuring and impairment charges 28,000,000 54,000,000 $ 69,000,000    
Invigorate Program | Property, Plant and Equipment          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Total restructuring and impairment charges     14,000,000    
Facility-Related Costs          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Total restructuring and impairment charges   29,000,000      
UMass Joint Venture          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Ownership percentage by noncontrolling owners         18.90%
Level 3 | Contingent Consideration          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Total fair value adjustments included in earnings - unrealized 2,000,000 11,000,000      
Contingent consideration liability 106,000,000 104,000,000 $ 23,000,000    
Level 3 | Contingent Consideration | Other Liabilities          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Contingent consideration liability 101,000,000 99,000,000      
Level 3 | Contingent Consideration | Accounts Payable and Accrued Liabilities          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Contingent consideration liability $ 5,000,000 $ 5,000,000      
Haystack Oncology, Inc. | Additional, Based on Revenue          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Contingent consideration arrangements, range of outcomes, value, high       $ 100,000,000  
Haystack Oncology, Inc. | Additional, Reimbursement Coverage          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Contingent consideration arrangements, range of outcomes, value, high       $ 50,000,000  
Haystack Oncology, Inc. | Comparable Company Revenue Volatility          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Measurement input 0.35        
Haystack Oncology, Inc. | Comparable Company Revenue Volatility | Changing Comparable Company Revenue Volatility          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Measurement input 0.25        
Contingent consideration arrangements $ 5,000,000        
Haystack Oncology, Inc. | Comparable Company Revenue Volatility | Changing Discount Rate          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Contingent consideration arrangements $ 3,000,000        
Haystack Oncology, Inc. | Discount rate          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Measurement input 0.105        
Haystack Oncology, Inc. | Discount rate | Additional Impact          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Measurement input 0.05        
Haystack Oncology, Inc. | Discount rate | Changing Discount Rate          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Measurement input 0.070